Contamination Crackdown Forces Some Chinese Drugmakers to Halt Production

June 15, 2012
Several drugmakers in China are being ordered to power down production lines and hand over their licenses for producing capsule-based drugs after a crackdown on chromium contamination by the country’s regulatory agency. Some 13 percent of all drug-capsule makers in China were producing products with excessive, unsafe levels of chromium, China’s State Food and Drug Administration (SFDA) found. SFDA tested more than 11,500 batches of drugs and found 669 — or 5.8 percent — had chromium levels higher than the national pharmacopoeia standard.
Drug GMP Report